Informations générales (source: ClinicalTrials.gov)
CHOC - Implémentation et évaluation d'un Parcours de Soin Ambulatoire Pour Les Patients traités Par Voie Intra-artérielle d'un Cancer Primitif du Foie : Essai Multicentrique contrôlé randomisé
Interventional
N/A
University Hospital, Angers (Voir sur ClinicalTrials)
décembre 2025
juin 2028
11 mars 2026
Randomized trial comparing two care organizations (outpatient versus conventional
inpatient care) using a mixed method (quantitative and qualitative data and analysis).
The protocol involves randomization between an ambulatory group and a conventional
hospitalization group. Patients will be monitored for 7 months to assess satisfaction,
complications and treatment efficacy. A qualitative study will be carried out to
understand the obstacles and facilitate implementation of the ambulatory pathway. A
medico-economic analysis will accompany this study to assess the financial impact of
adopting the ambulatory pathway. The expected results will help determine the best
management strategy for these patients.
The study's hypotheses are that performing intra-arterial treatments for primary liver
cancer on an outpatient basis, combined with telephone follow-up, will improve patient
satisfaction with their care, and that analysis of the implementation of this outpatient
pathway will help improve the pathway and facilitate its implementation at other sites,
by identifying obstacles and solutions.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Paul BEUNON | 30/04/2026 08:50:04 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP - Hôpital Avicenne | Olivier SUTTER, Dr | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Beaujon | Jules GREGORY, Dr | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Cochin | BARAT Maxime, Dr | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| University hospital of Besançon - 25030 - Besançon 3033123 - France | Paul CALAME, Dr | Contact (sur clinicalTrials) | |||
| University hospital of Grenoble-Alpes - 38700 - La Tronche 3006131 - France | Julien GHELFI, Dr | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Hospital of Pitié-Salpétrière (AP-HP) - 75013 - Paris 2988507 - France | Charles ROUX, Dr | Contact (sur clinicalTrials) | |||
| Hospital of Vendée - 85925 - La Roche-sur-Yon 3006767 - France | Nadia MOUSSA, Dr | Contact (sur clinicalTrials) | |||
| Nantes - 44093 - Nantes 2990969 - France | Frédéric DOUANE, Dr | Contact (sur clinicalTrials) | |||
| University hospital of Amiens - 80054 - Amiens 3037854 - France | Thierry YZET, Dr | Contact (sur clinicalTrials) | |||
| University hospital of Angers - 49933 - Angers 3037656 - France | Christophe AUBE, Pr | Contact (sur clinicalTrials) | |||
| University hospital of Brest - 29609 - Brest 3030300 - France | Jean-Romain RISSON, Dr | Contact (sur clinicalTrials) | |||
| University hospital of Clermont-Ferrand - 63003 - Clermont-Ferrand 3024635 - France | Benoît MAGNIN, Dr | Contact (sur clinicalTrials) | |||
| University hospital of Montpellier - 34090 - Montpellier 2992166 - France | Boris GUIU, Pr | Contact (sur clinicalTrials) | |||
| University hospital of Nice - 06202 - Nice 2990440 - France | Patrick CHEVALLIER, Dr | Contact (sur clinicalTrials) | |||
| Univesity hospital of Bordeaux - 33607 - Pessac 2987805 - France | Panteleimon PAPADOPOULOS, Dr | Contact (sur clinicalTrials) | |||
Critères
Tous
- Age ≥ 18 years
- HCC or CCi diagnosed according to the criteria of the European Association for the
Study of the Liver (2024) or histologically proven.
- HCC or CCi naive to intra-arterial treatment. HCC may have been previously treated
with other non-intra-arterial therapies. Other HCC may have been previously treated
but not with intra-arterial therapy.
- If HCC treatment is proposed at a Multidisciplinary Consultation Meeting (RCP):
- Patient Child-Pugh < B8
- Single or multiple HCC
- Absence of lobar or truncal portal obstruction
- Absence of bile duct dilatation
- If treatment by REH proposed in RCP:
- Absence of truncal portal tumor invasion
- Uni-lobar tumor invasion (except for centrohepatic CCi)
- Total bilirubin < 20 mg/l (or 35 µmol/L)
- Patient affiliated to or benefiting from a social security scheme
- Patient having signed an informed consent form
Exclusion Criteria:
- Technical contraindication or morphological elements of predictable technical
difficulty
- Chronic renal insufficiency (Clairance < 30 ml/min)
- Known allergy to a contrast agent or chemotherapy agent
- Patient unable to be a candidate for outpatient management
- Patient previously included in the study
- Patient who, for psychological, social, family or geographical reasons, could not be
regularly monitored, patient who, for psychological, social, family or geographical
reasons, could not be followed regularly
- Concomitant disease or severe uncontrolled clinical situation
- Severe uncontrolled infection
- Pregnant, breast-feeding or parturient woman
- Person deprived of liberty by judicial or administrative decision
- Person under compulsory psychiatric care
- Person under a legal protection measure
- Person unable to give consent